Investors should monitor initiation of the Phase 3 RESCUE program in mid-2026 and initial 3-month NDV-01 data from the 2L BCG-unresponsive study expected by year-end 2026. The combination of strong Phase 2 durability, clean safety profile, and extended funding significantly de-risks near-term development and increases probability of regulatory success.
RLMD drugs
RLMD drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 20 $6.07entry
- T+1 · 8mo ago −3.46%α −4.56% · $5.86
- T+5 · 8mo ago +5.93%α +8.08% · $6.43
- T+20 · 7mo ago +21.42%α +12.10% · $7.37
- T+60 · 5mo ago +4.94%α −9.48% · $6.37
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Relmada Therapeutics reported financial results for 2025 and provided a corporate update highlighting positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC), showing a 76% durable complete response rate and favorable safety. The company secured $160 million in PIPE financing in March 2026, boosting its cash runway through 2029 to fund the upcoming Phase 3 RESCUE program. Despite a reduced net loss, the company remains pre-revenue with no near-term earnings inflection.
Key Financial Metrics
Key Facts
- NDV-01 Phase 2 data shows 76% complete response (CR) rate at 12 months and 95% CR at any time in high-risk NMIBC; 80% CR at 12 months in BCG-unresponsive patients
- No Grade ≥3 treatment-related adverse events or treatment discontinuations observed
- FDA alignment confirmed on two registrational pathways for NDV-01: adjuvant intermediate-risk NMIBC and 2L BCG-unresponsive NMIBC
- Oversubscribed $160 million PIPE financing completed in March 2026, led by top healthcare investors
- Cash balance of $93.0 million as of December 31, 2025, now expected to fund operations through 2029 including Phase 3 development
- Phase 3 RESCUE program initiation expected mid-2026; U.S. IND clearance also anticipated mid-2026
- Net loss for 2025 was $57.4 million ($1.45/share), improved from $80.0 million ($2.65/share) in 2024
Financial Impact
Cash runway extended to 2029 with $253M total liquidity (existing $93M + $160M PIPE); R&D spend decreased 42% YoY to $26.9M due to completion of prior trials
Risk Factors
- Phase 3 trial may not replicate Phase 2 efficacy or safety results
- Regulatory delays or failure to maintain alignment with FDA on trial design
- Dilution risk from future financings if additional capital is needed beyond 2029
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259417 |
Track record
11 reports on RLMD
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
- Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
- Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
- May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
- May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
- Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
- Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Viewing Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
- Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers